To demonstrate the superiority of estradiol valerate plus dienogest ( E ( 2 ) V/DNG ) over ethinylestradiol plus levonorgestrel ( EE/LNG ) in reducing the number of days with dysmenorrheic pain among women with primary dysmenorrhea .